论文部分内容阅读
采用小剂量去甲氧柔红霉素(IDA)加阿糖胞苷和足叶乙甙治疗老年性急性髓系白血病(AML)并评价其药代动力学、临床疗效及其耐受性。 26名老年AML患者,年龄61～75岁,男10例,女16例.M_02例、M_18例、M_35例、M_47例、M_54例;9例过去有骨髓增生异常综合征病史。诱导治疗方案:IDA8mg/m~2快速静滴第1、3、5天,阿糖胞苷(Arac)200mg/m~2持续静滴第1～7天,足叶乙甙(VP-16)60mR/m~2静滴第1～5天;未达完全缓解者以同样方案重复第2疗程。缓解后治疗方案:IDA第1、3天,
A small dose of idarubicin (IDA) plus cytarabine and etoposide was used to treat senile acute myeloid leukemia (AML) and to evaluate its pharmacokinetics, clinical efficacy, and tolerability. Twenty-six elderly AML patients aged 61 to 75 years old, 10 males and 16 females. M_02 cases, M_18 cases, M_35 cases, M_47 cases, M_54 cases; 9 cases had a history of myelodysplastic syndrome in the past. Induction therapy: IDA 8mg/m~2 rapid intravenous infusion on days 1, 3, and 5, AraC 200mg/m~2 continuous intravenous infusion on the 1st to 7th days, and etoposide (VP-16) 60mR/m~2 intravenous infusions on days 1 to 5; patients who did not achieve complete remission were repeated on the same schedule for the second course of treatment. After remission treatment program: IDA 1, 3,